UBS AM’s AVANIR PHARMACEUTICALS, INC CL A AVNR Stock Holding History

UBS AM’s Portfolio AVNR Stock Details AVNR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-115,894	Closed	-$1.96M	–	2685
2014 Q4	$1.96M	Buy	115,894 +14,000	+14%	+$197K	﹤0.01%	1330
2014 Q3	$1.22M	Buy	101,894 +2,800	+3%	+$19.1K	﹤0.01%	1493
2014 Q2	$559K	Buy	99,094 +22,300	+29%	+$103K	﹤0.01%	1852
2014 Q1	$282K	Buy	76,794 +24,300	+46%	+$92.6K	﹤0.01%	2222
2013 Q4	$176K	Buy	52,494 +9,600	+22%	+$39.6K	﹤0.01%	2407
2013 Q3	$182K	Hold	42,894	–	–	﹤0.01%	2362
2013 Q2	$197K	Buy	+42,894	New	+$147K	﹤0.01%	2268

UBS AM's AVNR Position: Q1 2015 in Review

UBS AM sold out of AVANIR PHARMACEUTICALS, INC CL A (AVNR) in Q1 2015, closing a stake of 115,894 shares — an estimated $1.96M sold.

UBS AM first reported a position in AVNR in Q2 2013 and held it in 7 quarters. The position peaked at $1.96M in Q4 2014. 0 funds tracked by Wall St. Rank hold AVNR as of Q1 2015.

UBS AM reported no remaining AVANIR PHARMACEUTICALS, INC CL A position as of Q1 2015 after selling out during the quarter.
UBS AM sold 115,894 AVANIR PHARMACEUTICALS, INC CL A shares in Q1 2015, an estimated $1.96M.
UBS AM first reported a position in AVANIR PHARMACEUTICALS, INC CL A in Q2 2013 and held it in 7 quarters.
UBS AM's AVANIR PHARMACEUTICALS, INC CL A position peaked at $1.96M in Q4 2014.
0 funds tracked by Wall St. Rank held AVANIR PHARMACEUTICALS, INC CL A as of Q1 2015.

Based on UBS AM's 13F filing for Q1 2015, filed 4 May 2015.